SOLICITATION NOTICE
B -- Analytical Services for Identification of Novel Cytokines
- Notice Date
- 1/12/2010
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100002-KM
- Archive Date
- 2/11/2010
- Point of Contact
- Karri L. Mares, Phone: 3014357774, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
maresk@mail.nih.gov, cr214i@nih.gov
(maresk@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6070, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Center for Cancer Research (CCR), Metabolism Branch (MB) plans to procure on a sole source basis the services of Transponics; P.O. Box 1037; Mount Wolf, PA 17437 to provide Analytical Services for Identification of Novel Cytokines. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). Only one award will be made as a result of this solicitation, this is a firm fixed price award. Period of Performance: Performance shall be for twelve (12) months from date of award with three (3), twelve (12) month option periods. The purpose of this requirement is the isolation and characterization of a novel signaling pathway used by IL-15/IL-15R which is mediated by IL-15 stimulated mixtures of T-cell and dendritic cells that is not mediated by IL-15 stimulated T-cells alone, as well as isolation and characterization of a specific novel and previously undefined cytokine called IL-X and the molecular cloning of its receptors, its signaling pathways and the genes encoding it. These latter agents, once characterized, will be used in pre-clinical models to test therapeutic regimens for cancers and autoimmune diseases. The Contractor shall provide recommendations and guidance on strategies and proteomic analyses as part of the IL-15/IL-15R signaling project. The contractor shall develop T-cell lines and T-T hybridomas that produce the biologically active factor that is required for NK and T-cell proliferation and survival; generate cDNA libraries from cell producing cytokines; and use of these libraries in the cloning by expression of gene encoding the novel cytokine; purify and characterize the biologically active factor using classical protein purification and characterization techniques including HPLC and mass spectroscopy; define the receptor used by the novel cytokine on T and NK-cells; determine the functional activities of the novel cytokine on T and NK-cell proliferation, differentiation and function; define the role of the cytokine in the pathogenesis of immunodeficiency, autoimmune diseases and leukemia/lymphoma. Transponics is the the only source known to the NCI that has the experience and background knowledge in identification and analysis of the novel cytokine IL-X, and the genes and receptors regulating IL-X. Transponics was the only source known with staff experienced in the co-discovery of the cytokine interleukin-15, the definition of its receptors, and in the characterization of the IL-15R in terms of its structure and signaling pathways (Dr. Bamford with Dr. Waldmann in 1994 discovered that IL-15R beta is required for IL-15 signaling) Furthermore, Transponics has the historical knowledge, experience and direct involvement in the present project with its gene isolation and modification, cDNA cloning, protein purification, culture of T-cells and in the definition of functions of the IL-X cytokine that acts on T and NK-cells. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office on or before 11:00 AM EST on January 27, 2010. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI contracting office to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Karri Mares, Contract Specialist at maresk@mail.nih.gov. A determination by the Government not to compete this proposed award based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100002-KM on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100002-KM/listing.html)
- Record
- SN02040151-W 20100114/100112234620-fddc3b698b06f4fc23fe76fca5dc2922 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |